What is the role of pre-exposure prophylaxis in HIV infection prevention?

Updated: Jan 02, 2020
  • Author: Robert J Carpenter, DO, FACP; Chief Editor: John Bartlett, MD  more...
  • Print


A multinational study, called the Pre-exposure Prophylaxis Initiative (iPrEx) trial, found that once-daily emtricitabine plus tenofovir disoproxil fumarate (FTC-TDF) reduced the risk of acquiring HIV by 44% in a study population of high-risk, HIV-negative men or transgender women who have sex with men. This efficacy increased to 92% in patients who had any detectable drug in their system and to more than 99% in those with blood levels consistent with daily use. [13]

Additional studies have been completed or are ongoing in serodiscordant heterosexual couples and intravenous drug users. [14, 15] The CDC has updated interim guidance for pre-exposure prophylaxis (PrEP) in these groups. [16] For more information, see Preexposure HIV Prophylaxis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!